Demant A/s · OMXCOP:DEMANT
Demant A/s — Q1 2026 Earnings Presentation
18 slides from Demant A/s's earnings presentation, May 6, 2026
Slide 1: Interim Management Statement Q1 2026
Interim Management Statement Q1 2026 6 May 2026 Søren Nielsen, President & CEO René Schneider, CFO Investor Relations 1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements that reflect Demant’s current expectations regarding future events and financial performance. Forward-looking statements are statements other than historical facts and include, without limitation, statements that may pr
Slide 3: Agenda
Agenda Business highlights and key financial takeaways Business area review Outlook for 2026 Q&A 3
Slide 4: Business highlights Q1 2026
Business highlights Q1 2026 Strong start to the year with 6% organic growth for the 1 Group, which is at the high end of our expectations. Growth was supported by 10% growth from acquisitions Hearing Aids delivered very strong organic growth of 9% with growth momentum strongly fuelled by Oticon Zeal
Slide 5: Key financial takeaways for Q1 2026
Key financial takeaways for Q1 2026 Group organic growth of 6%, which is at the high end of our 6% expectations Revenue Growth Business area (DKK million) Q1 26 Q1 25 Org. Acq. LCY FX Rep. Gross margin increased primarily driven by a higher ASP in Hearing Aids, 3,356 3,148 11% 0% 11% -4% 7% Hearing
Slide 6: Business area review
Business area review 6
Slide 7: The hearing aid market in Q1 2026
The hearing aid market in Q1 2026 Estimated market growth: We estimate that overall unit growth was around 3% in Q1 2026, with growth being broad-based albeit slightly below the structural unit growth of rate of 4-6%, as expected. The ASP development is estimated to be around 1% due to 2025 2026 geo
Slide 8: Hearing Aids in Q1 2026
Hearing Aids in Q1 2026 Significant growth momentum following the launch of Oticon Zeal Comments Revenue and growth With the rollout of Oticon Zeal across all major markets in Q1, Revenue Growth growth momentum has seen strong improvement, supported (DKK million) Q1 26 Q1 25 Org. Acq. LCY FX Rep. by
Slide 9: The first hearing aid to do it all – unseen
The first hearing aid Discreet to do it all – unseen AI sound processing Connectivity Rechargeable Same-day fitting and flexibility 9 Oticon Zeal. The first hearing aid to do it all – unseen
Slide 10: Significant opportunity for Oticon Zeal and strong user acceptance
Significant opportunity for Oticon Zeal and strong user acceptance Oticon Zeal addresses the needs of Data from fittings of Zeal suggests Significant proportion of users decide more than half of current users: strong reception from first-time users: to have flexible fit domes: The addressable market
Slide 11: Strong market response and growth momentum following launch of Zeal
Strong market response and growth momentum following launch of Zeal Significant growth momentum Strong customer reception by new Roll-out continues with Oticon Zeal following the launch of Zeal: and existing customers: now available in all major markets: Following the launch of Oticon Zeal, Customer
Slide 12: Hearing Care in Q1 2026
Hearing Care in Q1 2026 Continuously good performance with the integration of KIND progressing as planned Comments Revenue and growth 26% growth in local currencies driven by a significant Revenue Growth contribution from acquisitions of 23%, largely due to the (DKK million) Q1 26 Q1 25 Org. Acq. LC
Slide 13: Diagnostics in Q1 2026
Diagnostics in Q1 2026 Diagnostics had a good start to the year Comments Revenue and growth Following a good end to 2025, the market for diagnostic Revenue Growth instruments and services is estimated to have seen slight (DKK million) Q1 26 Q1 25 Org. Acq. LCY FX Rep. growth in Q1 Diagnostics 588 60
Slide 14: Outlook for 2026
Outlook for 2026 14
Slide 15: 2026 outlook assumptions
2026 outlook assumptions Outlook assumptions are unchanged Market Demant Due to general macroeconomic uncertainty, we expect the value We have launched a company-wide initiative for Demant to improve growth rate in the global hearing aid market to be 2-4% in 2026, which profitability, which is expec
Slide 16: Financial outlook for 2026
Financial outlook for 2026 The outlook for 2026 is maintained, however the strong reception of Oticon Zeal in Q1 makes results at the lower end of the organic growth and EBIT before special items ranges less likely: Metric Outlook Organic growth 3-6% EBIT before special DKK 4,100-4,500 million items
Slide 17: Q&A
Q&A ,
Slide 18: Save the date: Capital Markets Day
Save the date: Capital Markets Day Tuesday, 24 November 2026 Demant headquarters, Copenhagen, Denmark 18 18